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Background: Evidence about the effect of initiating efavirenz-
containing combination antiretroviral therapy (ART) as the first-line
therapy on suicidal thoughts remains conflicting.
Methods: Using data from a cohort of HIV-infected adults enrolled
in routine care across 5 sites in the United States, we included
participants with a baseline patient-reported outcome measure and
detectable viral load who initiated ART between 2011 and 2014.
Participants were followed until the earliest of the following: first
suicidal thoughts, discontinuation of initial ART regimen, death, loss
to care (.12 months with no HIV appointments), or administrative
censoring (2014–2015). Suicidal thoughts were measured using
a Patient Health Questionnaire-9 item. We used weighted marginal
structural Cox models to estimate the effect of initiating efavirenz-
containing ART, versus efavirenz-free ART, on the hazard of active
or passive suicidal thoughts after ART initiation, accounting for
confounding by channeling bias.
Results: Overall, 597 participants were followed for a median of 19
months (13,132 total person-months); 147 (25%) initiated efavirenz-
containing ART. At ART initiation, 38% of participants reported
suicidal thoughts or depressive symptoms. Initiating efavirenz-based
ART was associated with a hazard ratio (HR) for suicidal thoughts
below the null in the crude analysis [HR, 0.88; 95% confidence
interval (CI): 0.53 to 1.45] and above the null in the weighted analysis
(HR, 1.21; 95% CI: 0.66 to 2.28). Among those with a prior mental
health issue, the weighted HR was 1.76 (95% CI: 0.45 to 6.86).
Conclusions: After accounting for measured channeling bias, we
observed no strong evidence that initiating efavirenz-containing
ART increased the hazard of suicidal thoughts.
Key Words: HIV, efavirenz, suicidal thoughts, suicidal ideation,
antiretroviral therapy
(J Acquir Immune Defic Syndr 2017;76:402–408)
INTRODUCTION
Efavirenz, a nonnucleoside reverse transcriptase inhib-
itor, has been a mainstay of antiretroviral therapy (ART) for
more than 15 years. Use of efavirenz is declining in the
United States because of the availability and tolerability of
newer agents.1 However, the World Health Organization
continues to recommend efavirenz globally as first-line
ART.2,3 Efavirenz is attractive given its rapid and durable
viral suppression, low cost, generic formulation, and avail-
ability in a fixed-dose combination pill.4 However, serious
psychiatric side effects, including suicidal thoughts, have
been reported with efavirenz.5 Given its widespread use, an
accurate understanding of the relationship between efavirenz
use and suicidal thoughts is critical.
Evidence about the effect of efavirenz on suicidal
thoughts remains conflicting. Early clinical trials suggested
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first-line ART in the United States4,14; n = 2729), at a site
collecting PRO information (n = 6 of 8 sites) and had a PRO
measure within the 6 months prior or 1 week after initiating
ART (n = 875). Participants who were already taking
efavirenz when PRO collection began may have previously
experienced psychiatric side effects from efavirenz that
resolved and therefore were excluded. Information on pre-
vious ART use is not always available in CNICS. Therefore,
participants with incomplete data on ART use (n = 40) or who
had a suppressed viral load at ART initiation (indicating
possible prior ART use; n = 223) were excluded. Participants
from 1 site where no patients initiated efavirenz (n = 15
participants) were excluded because this site may differ from
others where efavirenz was prescribed. Our interest was in
understanding suicidal thoughts occurring as a result of
initiating efavirenz. Furthermore, clinicians are unlikely to
have access to information on a patient’s suicidal thoughts
when making decisions about initial ART regimen. For these
reasons, patients with suicidal thoughts at ART initiation
were not excluded. Participants were followed from ART
initiation until the earliest of the following dates: a PRO
measure indicating suicidal thoughts, discontinuation of ART
(defined as switching to an efavirenz-containing or efavirenz-
free regimen, depending on initial regimen, or ART discon-
tinuation entirely), loss to HIV care (12 months with no
attended HIV appointments), or administrative censoring
(October 2014 to September 2015, depending on site).
Measures
The primary exposure was initial ART regimen,
categorized as efavirenz containing or efavirenz free. An
ART regimen was defined as being on $3 antiretroviral
drugs, including at least 1 nonnucleoside reverse transcriptase
inhibitor, protease inhibitor, or integrase inhibitor for $21
days.1 The outcome of interest was passive or active suicidal
thoughts (hereafter suicidal thoughts) following ART initia-
tion. Suicidal thoughts are measured as part of the CNICS
PROs using 1 item of the Patient Health Questionnaire-9
(PHQ-9),15 which asks in a combined question whether
participants had any thoughts of being better off dead
(passive) or hurting themselves (active) in the previous
2 weeks. The PHQ-9 is a validated measure to identify
suicidal thoughts, with a sensitivity of 65%–90% and
specificity of 80% to .90%.16,17 We did not evaluate
attempted or completed suicide or ART discontinuation
because of the psychiatric side effects. CNICS does not
collect information on reasons for ART discontinuation or
suicide attempts, and cause of death information is only
available for a portion of the population. Of those with cause
of death information, very few were reported as suicides.
CNICS PROs collect additional patient-reported data
using validated measures, including ART adherence (AIDS
Clinical Trials Unit-4 Visual Analog Scale, defined as no
missed doses in the past week18,19), depressive symptom
severity (defined as a binary measure with cutpoint PHQ-9 of
$10 and a continuous score15), panic disorder (PHQ-5,
defined as some panic disorder symptoms or panic disor-
der20), high-risk alcohol use [Alcohol Use Disorders
that efavirenz may increase the risk of depression and suicidal 
thoughts.6 However, side effects were thought to be rare, 
transient, and, in most cases, not life threatening. More 
recently, efavirenz was associated with a 2-fold increase in 
the hazard of a combined outcome of suicidal thoughts, 
behaviors, or attempted or completed suicide in a pooled 
analysis of 4 randomized controlled trials from the AIDS 
Clinical Trials Group.7 Efavirenz was also associated with 
suicidal behavior in a secondary analysis of the Strategic 
Timing of Antiretroviral Treatment (START) trial.8 These 
results were not confirmed by data from the Food and Drug 
Administration Adverse Event Reporting System (FAERS)9 
or when the relationship between efavirenz and completed 
suicide was evaluated in the Data Collection on Adverse 
Events of Anti-HIV Drugs (D:A:D) Study.10
Two key considerations in studying the relationship 
between efavirenz and suicidal thoughts are accurate mea-
surement of suicidal thoughts and the appropriate accounting 
for confounding by selective prescription or discontinuation 
of efavirenz. Previous analyses of efavirenz’s effect on 
suicidal outcomes have relied on adverse event reporting7–
10 or insurance claims,11 which may capture the most severe 
forms of suicidal thoughts. Additionally, the potential for 
clinicians to prescribe efavirenz-free regimens to persons with 
mental health issues (channeling-in bias) or to switch persons 
who develop mental health issues off efavirenz (channeling-
out bias)12 is an important consideration that has not been 
fully accounted for in previous observational analyses.9,10
To address these questions, we used data from a cohort of 
HIV-infected adults in routine care across the United States who 
complete routine systematic assessments of suicidal thoughts 
every 4–6 months. The goal of our analysis was to estimate the 
effect of initiating efavirenz-containing ART as first-line therapy 
on time to passive or active suicidal thoughts.
METHODS
Data for the present analysis come from the Centers for 
AIDS Research Network of Integrated Clinical Systems 
(CNICS) cohort. The CNICS cohort includes more than 
31,000 HIV-infected adults in routine care at 8 sites in the 
United States.13 CNICS captures comprehensive clinical data 
that includes standardized diagnosis, medication, laboratory, 
and demographic information collected through electronic 
medical records and institutional data systems. Participants 
also complete self-administered questionnaires, or patient-
reported outcomes (PROs), on touch-screen tablets as a part 
of routine care. PROs are completed approximately every 4–6 
months, with variation based on clinical follow-up. Partic-
ipants provide written informed consent to participate in 
CNICS. Ethical approval for the use of routinely collected 
clinical data was provided by the institutional review board at 
each CNICS site.
Study Population
Participants in CNICS were included if they initiated 
ART between 2011 and 2014 (time frame when PRO 
data were available and efavirenz was recommended as the
Identification Test (AUDIT), defined as AUDIT score $4 for
males and $3 for females21], and current or past illicit drug
use, excluding marijuana [Alcohol, Smoking and Substance
Involvement Screening Test (ASSIST)22,23]. Baseline depres-
sive symptoms and suicidal thoughts were combined into
a 3-level variable: no depressive symptoms or suicidal
thoughts, depressive symptoms without suicidal thoughts, or
suicidal thoughts (with or without depressive symptoms),
because of the collinearity issues in the weighted model
between depressive symptoms and suicidal thoughts.
Self-reported race/ethnicity was categorized as white,
black, Hispanic, or other and HIV acquisition risk group as
men who had sex with men (MSM), heterosexuals, intrave-
nous drug users, or other and collected at CNICS enrollment.
CNICS captures prior clinician-documented mental health or
medical diagnoses in the medical record. We defined a prior
medical diagnosis as any previous medical diagnosis at the
time of ART initiation. A prior mental health disorder was
defined as any previous diagnosis of depression, bipolar
disorder, posttraumatic stress disorder or psychosis, as these
diagnoses are most likely to affect suicidal thoughts and
influence efavirenz prescription.24,25 Undetectable viral load
was defined as ,50 copies per milliliter.
Statistical Analysis
The goal of our analysis was to estimate the effect of
initiating efavirenz-containing ART on time to suicidal
thoughts. We used weighted Kaplan–Meier curves and mar-
ginal structural Cox models with inverse probability
weights26 to approximate a study in which individuals were
randomized at baseline to initiate efavirenz-containing or
efavirenz-free ART. We developed 3 sets of weights; inverse
probability of treatment weights (IPTW) to account for
potential channeling-in bias in receipt of efavirenz, inverse
probability of censoring weights to account for bias because
of loss to follow-up, and inverse probability of observation
weights to account for the varying frequency of PRO
measurements between participants. Additional details about
the creation of the weighs are available in the Supplemental
Digital Content, http://links.lww.com/QAI/B66. Directed
acyclic graphs were used to identify covariates for inclusion
in each set of weights.27 For all weights, restricted cubic
splines28 were used for continuous variables whenever possi-
ble; any categorization was based on the functional form of the
relationship between the covariate and outcome. Because of the
limited sample size, for both race/ethnicity and HIV acquisi-
tion, participants reporting “other” were collapsed with the
largest category (white and MSM) for statistical analyses.
We conducted 3 secondary analyses. First, we exam-
ined mental health status at baseline (defined as a prior mental
health diagnosis, reported panic symptoms or disorder,
depressive symptoms/suicidal thoughts, or an antidepressant
prescription at ART initiation) as an effect measure modifier
of the efavirenz–suicidal thoughts relationship. Second, we
considered ART for $7 days as an ART regimen. Third, we
examined an outcome of more frequent suicidal thoughts
(defined as occurring half the days or more in the past
2 weeks). We compared crude and weighted estimates for
both the primary and secondary analyses and assessed the
proportional hazards assumption. All analyses were con-
ducted in Stata version 13 (StataCorp, College Station, TX) or
SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Overall, 597 CNICS participants met our inclusion
criteria (Fig. 1). Characteristics between all those who
initiated ART, those without a valid PRO, and the study
population were similar (Table S2). At ART initiation, 147
(25%) initiated efavirenz-containing ART. Additional infor-
mation on initial ART regimens in available in Table S3.
Participants were followed for a median of 19 months and
contributed 13,132 person-months of follow-up. Overall,
participants were predominately male subjects (90%), white
non-Hispanic/other (57%), and reported contracting HIV
through being MSM/other (74%; Table 1). Mental health
issues were common. At ART initiation, more than one-third
(38%) reported depressive symptoms (20%) or suicidal
thoughts and/or depressive symptoms (18%), 11% were
prescribed antidepressants, and 31% had a prior depression,
posttraumatic stress disorder, or bipolar or psychosis diagno-
sis. During the follow-up period, 89 participants (15%)
reported suicidal thoughts after ART initiation, 4 (1%) died,
140 (23%) were lost to follow-up, 74 (12%) discontinued
ART, and 290 (49%) were administratively censored.
FIGURE 1. Inclusion criteria for 597 HIV-in-
fected adults in CNICS who initiated ART 
between 2011 and 2014 and had a PRO within 
6 months prior or up to 1 week after initiating 
ART and had a detectable viral load at ART 
initiation.
In the crude analysis, those starting efavirenz-
containing ART reported a slightly lower hazard of suicidal
thoughts than those starting efavirenz-free ART [hazard ratio
(HR), 0.88; 95% confidence interval (CI): 0.53 to 1.45;
Table 2]. At 36 months after ART initiation, the unadjusted
risk of suicidal thoughts for persons initiating efavirenz-free
ART was 21% and for persons initiating efavirenz-containing
ART was 19% (risk difference, 20.02; 95% CI: 20.12 to
0.06; Table 3 and Fig. 2).
In the weighted analysis, those starting efavirenz-
containing ART evidenced a slightly higher (but less precise)
hazard of suicidal thoughts than those starting efavirenz-free
ART (HR, 1.21; 95% CI: 0.65 to 2.28; Table 2). At 36
months after ART initiation, the weighted risk of suicidal
thoughts for persons initiating efavirenz-free ART was 22%
compared with 25% for persons initiating efavirenz-
containing ART (risk difference, 0.03; 95% CI: 20.10 to
0.25; Table 3 and Fig. 2). Covariates included in the IPTW
were no longer associated with efavirenz initiation in the
weighted analysis (Table S1). The proportional hazards
assumption was met in the crude analysis (exposure by log
time interaction; P value of 0.33) but not in the weighted
analysis (P-value 0.02); however, this is likely because of the
relatively constant risk of suicidal thoughts for efavirenz users
during year 2 (Fig. 2).
Weighted effect estimates were similar in a secondary
analysis where the minimum time on an ART regimen was 7
days (HR, 1.28; 95% CI: 0.67 to 2.43). When baseline mental
health status was considered as an effect measure modifier,
effect estimates suggested that initiating efavirenz-containing
ART may have a strong effect among those with mental health
issues (HR, 1.76; 95% CI: 0.45 to 6.86; HR among those
without mental health issues: 0.96; 95% CI: 0.23 to 4.01);
however, confidence intervals were wide and overlapping. In
a secondary analysis examining an outcome of more frequent
suicidal thoughts, the HR was 0.61 (95% CI: 0.10 to 3.62),
although there were a small number of events (n = 28).
DISCUSSION
In our cohort of HIV-infected adults initiating ART
between 2011 and 2014, 25% of participants initiated ART-
containing efavirenz and 15% of participants reported
experiencing suicidal thoughts over a median of 19 months
(76 weeks) of follow-up. The crude analysis indicated that
those starting efavirenz-containing ART were slightly less
likely to have suicidal thoughts. In contrast, in the weighted
analysis, those starting efavirenz-containing ART were
slightly more likely to have suicidal thoughts, after account-
ing for channeling bias, informative censoring, and missing
data. In both cases, the effect estimates were modest and 95%
confidence intervals included the null. When stratified by
baseline mental health status, effect estimates suggested that
efavirenz may have a stronger effect on suicidal thoughts
among those with a prior mental health diagnosis. Our results
were robust to changes in the specification of the minimum
length of an ART regimen and when an outcome of more
frequent suicidal thoughts was considered.
TABLE 1. Clinical and Demographic Characteristics at ART











2011 79 (17.6) 76 (51.7)
2012 121 (26.9) 39 (26.5)
2013 138 (30.7) 25 (17.0)
2014 112 (24.9) 7 (4.8)
Age, yr 36 (28–44) 34 (29–47)
Gender
Male 396 (88.0) 139 (94.6)
Female 54 (12.0) 8 (5.4)
Race/ethnicity
White, non-Hispanic 219 (48.9) 75 (51.7)
Black, non-Hispanic 98 (21.9) 37 (25.5)
Hispanic 95 (21.2) 26 (17.9)
Other 36 (8.0) 7 (4.8)
HIV risk group
MSM 304 (67.6) 114 (78.1)
IDU 56 (12.4) 13 (8.9)
Heterosexual 69 (15.3) 19 (13.0)
Other 21 (4.7) 0 (0.0)
Depression and suicidal ideation
No depression or suicidal
ideation
268 (59.6) 102 (69.4)
Depression 90 (20.0) 27 (18.4)
Suicidal ideation, with or
without depression
92 (20.4) 18 (12.2)
Antidepressant use
Not on an antidepressant 390 (87.4) 136 (93.8)
On an antidepressant 56 (12.6) 9 (6.2)
Panic disorder
No symptoms 279 (62.3) 116 (80.6)
Some symptoms 93 (20.7) 16 (11.1)
Panic disorder 76 (17.0) 12 (8.3)
Drug use
No use 166 (42.7) 72 (50.7)
Current use 113 (29.0) 29 (20.4)
Past use 110 (28.3) 41 (28.9)
Alcohol use
Not at risk drinking 107 (24.3) 42 (29.2)
At risk drinking 333 (75.7) 102 (70.8)
Prior mental health diagnosis*
No 305 (67.8) 107 (72.8)
Yes 145 (32.2) 40 (27.2)
Prior medical diagnosis*
No 386 (85.8) 129 (87.8)
Yes 64 (14.2) 18 (12.2)
CD4 count, cells/mm3 390 (241–545) 417 (276–530)
Missing data: race/ethnicity, n = 4; HIV risk group, n = 1; antidepressant use, n = 6;
panic disorder, n = 5; drug use, n = 66; alcohol use, n = 13; CD4 count, n = 3.
*At the time of ART initiation.
IDU, intravenous drug use.
Our findings are consistent with the results of 2
observational analyses examining the relationship between
efavirenz use and suicidal thoughts or behaviors.9,11 An
analysis of current efavirenz use and completed suicide,
which did not account for channeling bias in efavirenz
prescription, also showed no evidence of an association.10
However, a pooled analysis of 4 clinical trials found that
participants randomized to an initial ART regimen with
efavirenz had twice the hazard of developing suicidal
thoughts, attempting, or completing suicide (composite out-
come) over a median of 96 weeks of follow-up, compared
with those randomized to efavirenz-free ART.7 A secondary
analysis of the SMART trial, which randomized participants
to immediate versus delayed ART initiation, also found an
increased risk of suicidal behavior among participants who
initiated efavirenz in the immediate arm, compared with those
in the deferred arm before they initiated ART.8
Differences in the measurement of suicidal thoughts may
lead to conflicting evidence about efavirenz’s effect on suicidal
behaviors. In our analysis, suicidal thoughts were measured
systematically and at regular intervals using the PHQ-9, as part
of the PROs.15 In previous studies, including clinical trials,
suicidal thoughts have been measured using adverse event–
reporting systems.7–10 Adverse event–reporting systems may
be more likely to capture severe active suicidal thoughts rather
than the broader pool of passive or active suicidal thoughts
measured by the PHQ-9.29 It is possible that efavirenz in-
creases the more severe form of active suicidal thoughts, which
may help to explain the effect of efavirenz on suicidal thoughts
and behavior observed in clinical trials. However, this
hypothesis has not been tested. Passive thoughts are much
more common than active thoughts29 and may help to explain
the attenuated result in this study.
A strength of this study is the use if IPTWs to address
channeling-in bias. Reports of psychiatric side effects from
efavirenz have led many clinicians to avoid prescribing
efavirenz for persons with a mental health diagnosis (“chan-
neling-in”) and to switch persons who develop mental health
issues off efavirenz (“channeling-out”).12 Although CNICS
does not collect information on provider reasons for pre-
scription or discontinuation, our analysis, and others, ad-
dressed channeling-in bias by balancing measured covariates
between those initiating efavirenz and those not through
IPTWs.11 In our weighted data, none of the variables included
in the IPTW were associated with efavirenz use (Table S1),
suggesting that the IPTW properly balanced the likelihood of
receiving efavirenz conditional on included and measured
covariates. However, residual confounding by unmeasured,
and possibly difficult to measure, factors may remain. In our
analysis, channeling-out bias was considered negligible
because of the small number of persons who discontinued
ART during the follow-up period.
In our cohort, 89 persons experienced suicidal
ideation during follow-up. This was higher than the
number of events reported in the pooled analysis of 4 trials
from the AIDS Clinical Trials Group (47 events in the
efavirenz group and 15 events in the efavirenz-free group)
that reported an HR of 2.28 for composite suicidal
behaviors or suicide with efavirenz use.7 Thus, the wide
confidence intervals reported in our analysis are unlikely to
be driven solely by a lack of statistical power. Of note, the
confidence interval for our weighted estimate did overlap
with the results reported in the pooled analysis. Although
our sample size (N = 597) may be small relative to the
larger CNICS cohort, a larger source of observational data
with validated measures of suicidal thoughts is unlikely to
be available in the future.
As with all observational data, the internal validity of
our findings rests on several assumptions. Our analysis
assumes no unmeasured confounding and correct model
TABLE 2. HR for the Effect of Initiating Efavirenz-Containing ART on Time to Suicidal Thoughts Among 597 HIV-Infected Adults
Initiating ART Between 2011 and 2014
Initial ART Regimen No. Events Person Months Incidence Rate*
Unadjusted Weighted
HR (95% CI) HR (95% CI)2
Efavirenz-free ART 69 9690 7.12 1.00 1.00
Efavirenz-containing ART 20 3442 5.81 0.88 (0.53 to 1.45) 1.21 (0.65 to 2.28)
Weighted to account for potential channeling-in bias in efavirenz prescription, missing PRO assessments, and informative censoring because of loss to follow-up. Mean of
combined weights is 0.99 (range, 0.15–7.67).
*Incidence rate per 1000 person-months.2
TABLE 3. Risks and Risk Differences (RD) for Suicidal Thoughts 6, 12, and 36 Months After ART Initiation by Initial ART Regimen











Containing ART RD (95% CI)*
12 months 0.12 0.10 20.02 (20.07 to 0.04) 0.10 0.13 0.03 (20.02 to 0.10)
36 months 0.21 0.19 20.02 (20.12 to 0.06) 0.22 0.25 0.03 (20.10 to 0.25)
*95% CI are derived from bootstraps (n = 1000 for crude risk differences and n = 100 for weighted risk differences, due the large size of the data set).
results from those seen in randomized controlled trials may
stem from important differences in study populations, or
more likely, from the fact that adverse event–reporting
systems in clinical trials are more likely to capture more
sever forms of suicidal thoughts. Notably, similar pro-
portions of participants with prior mental health diagnoses
were included in our study and clinical trials,7 suggesting
that differences in study populations are unlikely to fully
explain disparate results.
In our analysis of HIV-infected adults in routine care,
initiating efavirenz-containing ART did not result in an
increased hazard of suicidal thoughts. Our results come from
one of the largest sources of data on efavirenz use among
HIV-infected adults in the United States; however, they may
be less generalizable to resource-limited settings where
fewer drug choices could lead to less channeling of
efavirenz, and mental health issues may be less likely to
be recognized or treated.34,35 Given the widespread and
continuing use of efavirenz globally, screening for and
monitoring suicidal thoughts among efavirenz users is
recommended. Further research is needed, particularly in
global settings, to clarify the relationship between efavirenz
and suicidal thoughts.
FIGURE 2. Unadjusted (A) and weighted (B) Kaplan–Meier curves showing the cumulative probability of suicidal ideation for
individuals who initiated efavirenz-containing ART and those who initiated efavirenz-free ART in CNICS between 2011 and
2014 through 36 months (1 event occurred after 36 months). Weighted estimates are weighted by the product of IPTW to
account for challenging-in bias, inverse probability of censoring weights to account for potentially informative loss to follow-
up, and inverse probability of observation weights to account for not having an observed PRO assessment at least once within
a 6-month period.
specification.30 We note the possibility of residual or 
unmeasured confounding and a violation of the proportional 
hazards assumption in the weighted analysis as limitations. 
Second, we assume consistency, or the idea that initiating 
efavirenz represents a well-defined treatment,31 a reasonable 
assumption given standardized current ART treatment guide-
lines. Finally, our analysis assumes that there is a nonzero 
probability for all participants of being in either exposure 
category (efavirenz containing or efavirenz free) within all 
strata of measured covariates in the data, also a plausible 
assumption.30 Finally, we note that our analysis focuses on an 
outcome of suicidal ideation; evidence about efavirenz’s 
relationship with major depression and other neuropsychiatric 
side effects, which may be independent of suicidal idea-
tion,32,33 have been reported elsewhere.12
Clinicians face difficult choices about whether to 
prescribe efavirenz, given its possible neuropsychiatric side 
effects. Our results from the largest cohort of HIV-infected 
adults in care in the United States suggest that initiating an 
efavirenz-containing regimen does not meaningfully 
increase the risk of suicidal thoughts. For participants with 
a history of mental health issues, efavirenz may have 
a stronger effect on suicidal thoughts. Differences in our
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